Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aquestive TherapeuticsAQST -1.15%49 Days Payable is 236.86 as of Jun. 2026, which is 23% above its 10-year median of 191.87. GuruFocus rates AQST with a GF Score™ of 49/100 and a GF Value™ of $2.37 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 925 Drug Manufacturers companies, Aquestive Therapeutics ranks better than 90.7% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aquestive Therapeutics Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Aquestive Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Aquestive Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aquestive Therapeutics (AQST) has a Days Payable of 236.86 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aquestive Therapeutics and its competitors. This is 23% above median its historical median of 191.87. Over the past decade, Aquestive Therapeutics' Days Payable has ranged from 147.93 to 394.89. According to the industry distribution chart, Aquestive Therapeutics ranks #86 out of 925 companies in the Drug Manufacturers industry, placing it in the top 9.3%.
Is Aquestive Therapeutics' Days Payable too high?
Aquestive Therapeutics' current Days Payable of 236.86 is 23% above median its 10-year median of 191.87. Over the past 10 years, this metric has ranged from a low of 147.93 to a high of 394.89. The Drug Manufacturers industry median Days Payable is 88.64. Aquestive Therapeutics' value of 236.86 is 167.2% above this industry median. Based on the distribution chart, Aquestive Therapeutics ranks #86 out of 925 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Aquestive Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aquestive Therapeutics' Days Payable compare to TLRY and EOLS?
According to the Drug Manufacturers industry distribution chart, Aquestive Therapeutics ranks #86 out of 925 companies for Days Payable. This places Aquestive Therapeutics in the top 9% of its industry — outperforming the majority of peers. The industry median Days Payable is 88.64. Aquestive Therapeutics' value of 236.86 is 167.2% above this benchmark. Historically, Aquestive Therapeutics' own Days Payable has ranged from 147.93 to 394.89 over the past decade. While the company's 10-year median is 191.87 vs. the industry median of 88.64, Aquestive Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.64, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aquestive Therapeutics's current Days Payable of 236.86 is 167.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aquestive Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aquestive Therapeutics's current Days Payable is 236.86, which is 23% above median its own 10-year median of 191.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aquestive Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aquestive Therapeutics (AQST) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.37, compared to a current price of $5.16 — trading 117.7% above its estimated fair value. The current Days Payable is 236.86, which is 23% above median its 10-year median of 191.87 and 167.2% above the Drug Manufacturers industry median of 88.64. Aquestive Therapeutics' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Aquestive Therapeutics (AQST), the current Days Payable is 236.86 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aquestive Therapeutics (AQST) Overvalued in 2026?
Based on GuruFocus' analysis, Aquestive Therapeutics stock appears to be overvalued.
The current stock price of $5.16 is trading 117.7% above its estimated GF Value™ of $2.37.
GuruFocus considers Aquestive Therapeutics to be Significantly Overvalued.
Key valuation signals for AQST:
Days Payable: 236.86 (23% above median its 10-year median of 191.87)
GF Value™: $2.37 vs. price of $5.16 (117.7% above fair value)
Industry Position: 167.2% above the Drug Manufacturers median (#86 of 925)
No single metric tells the full story. See the AQST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
49GF Score
Get the complete analysis for AQST
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQST has been successfully added to your 
